The Neurology Drug Development Commercial Landscape
The neurology market is entering a period of renewed momentum, with increasing investment across both early innovation and late‑stage, de‑risked assets, alongside growing competition for clinically validated programmes.
This Report Includes:
- Where capital is flowing in 2025–2026, including multi‑billion-dollar deals across neurodegeneration pipelines.
- Shifting deal dynamics, with a clear preference for phase 2 assets as companies wait for clinical proof of concept.
- Which targets are gaining momentum, from established players to rapidly emerging opportunities like huntingtin and B7-H3.
- How pipelines are evolving, with late‑stage assets driving near-term returns alongside continued early-stage innovation.
- The rise of advanced therapies, now accounting for a significant share of neurology development activity.
You May Also Be Interested In…
Learn More About Neuroscience
What is Beacon Neuroscience?
- The Most Comprehensive Way to Search the Neuroscience Drug Development Landscape: Unique search ontologies based on Neuroscience drug and trial characteristics
- Market Leading Approach to Neuroscience Preclinical & Clinical Data Curation: Manual curation of key Neuroscience research and development data points by Neuroscience research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Neuroscience company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
